LA JOLLA, Calif.–(BUSINESS WIRE)–The Calibr-Skaggs Institute for Innovative Medicines, the nonprofit drug development arm of Scripps Research, today announced two milestones in the clinical advancement of CLF065, its potential best-in-class, long-acting glucagon-like peptide-2 (GLP-2) receptor agonist in development for inflammatory bowel diseases (IBD). Calibr-Skaggs has enrolled the first patient in its Phase 2 study of CLF065 in chronic pouchitis and has filed an Investigational New Drug (
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
